This inventor holds 2 USPTO granted patents. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Saluggia, IT (2019)
- Slough, GB (2022)
Company Filing History:
Years Active: 2019-2022
Title: Mara Fortunato: Innovator in Biomarker Research
Introduction
Mara Fortunato is a distinguished inventor based in Saluggia, Italy. She has made significant contributions to the field of biomarker research, particularly in relation to IL-17 mediated diseases. With a total of 2 patents, her work is paving the way for advancements in therapeutic monitoring.
Latest Patents
Mara Fortunato's latest patents include the innovative use of lipocalin 2 (LCN2) as a biomarker for IL-17 inhibitor therapy efficacy. This invention provides a method for monitoring the response of patients to anti-IL-17 therapy, which is crucial for managing IL-17 mediated diseases. Her research highlights the importance of LCN2 in understanding treatment effectiveness.
Career Highlights
Throughout her career, Mara has worked with notable companies such as UCB Biopharma Sprl and UCB Biopharma Srl. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mara has collaborated with esteemed colleagues, including Adam Samuel Platt and Stephen Edward Rapecki. These partnerships have enriched her research and expanded the impact of her innovations.
Conclusion
Mara Fortunato is a remarkable inventor whose work in biomarker research is making a significant impact in the medical field. Her contributions are essential for advancing therapies for IL-17 mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile